Results 201 to 210 of about 3,480,967 (280)

Melatonin rhythms beyond the pineal organ: gene expression of receptors and biosynthesis enzymes in wild and F1 Senegalese sole. [PDF]

Fish Physiol Biochem
Félix F, Oliveira CCV, Martín I, Manchado M, Sánchez-Vázquez FJ, Cabrita E, Vera LM.   +6 more
europepmc   +1 more source

TRPM4 contributes to cell death in prostate cancer tumor spheroids, and to extravasation and metastasis in a zebrafish xenograft model system

Molecular Oncology, Volume 19, Issue 5, Page 1299-1309, May 2025.
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen, Saurav Subedi, Federico La Manna, Sofia Jarrin, Irida Papapostolou, Marianna Kruithof‐de Julio, Christine Peinelt   +6 more
wiley   +1 more source

SHORT-TERM PHOTIC REGULATION OF A RECEPTOR MECHANISM IN A DINOFLAGELLATE

, 1967
William G. Hand, Richard B. Forward, Demorest Davenport   +2 more
openalex   +2 more sources

Excitatory action of sympathomimetic amines on 5‐hydroxytryptamine receptors of gut [PDF]

, 1969
I. R. Innes, J D Kohli
openalex   +1 more source

Activation of Endoplasmic Reticulum-Localized Metabotropic Glutamate Receptor 5 (mGlu₅) Triggers Calcium Release Distinct from Cell Surface Counterparts in Striatal Neurons. [PDF]

Biomolecules
Jong YI, Harmon SK, O'Malley KL.
europepmc   +1 more source

Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer

Molecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti, Shingo Inagaki, Tuyen Thuy Bich Ho, Akihiro Seki, Keiko Yoshida, Kosuke Satomura, Yoshio Sakai, Shuichi Kaneko, Taro Yamashita   +8 more
wiley   +1 more source

Temporal mRNA Expression of Purinergic P2 Receptors in the Brain Following Cerebral Ischemia and Reperfusion: Similarities and Distinct Variations Between Rats and Mice. [PDF]

Int J Mol Sci
Challa SR, Levingston H, Fornal CA, Baker IM, Boston J, Shanthappa N, Unnam P, Klopfenstein JD, Veeravalli KK.   +8 more
europepmc   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Therapeutic Effects of Pharmacological Modulation of Serotonin Brain System in Human Patients and Animal Models of Fragile X Syndrome. [PDF]

Int J Mol Sci
Ciranna L, Costa L.
europepmc   +1 more source

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source